B. Riley Issues Positive Outlook for Vaxart Earnings

Vaxart, Inc. (NASDAQ:VXRT - Free Report) - Investment analysts at B. Riley lifted their Q3 2025 earnings estimates for Vaxart in a research report issued to clients and investors on Thursday, May 29th. B. Riley analyst M. Mamtani now expects that the biotechnology company will post earnings per share of ($0.04) for the quarter, up from their prior estimate of ($0.07). B. Riley currently has a "Buy" rating and a $2.00 price target on the stock. The consensus estimate for Vaxart's current full-year earnings is ($0.39) per share. B. Riley also issued estimates for Vaxart's Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.24) EPS, FY2026 earnings at ($0.14) EPS, FY2027 earnings at ($0.16) EPS and FY2028 earnings at ($0.02) EPS.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.07). The company had revenue of $20.88 million for the quarter, compared to the consensus estimate of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%.

Separately, Wall Street Zen upgraded Vaxart to a "hold" rating in a research report on Thursday, May 22nd.

Vaxart Trading Up 3.9%

NASDAQ VXRT traded up $0.02 on Monday, hitting $0.45. 1,334,989 shares of the company traded hands, compared to its average volume of 2,436,913. The company has a market capitalization of $102.70 million, a price-to-earnings ratio of -1.10 and a beta of 1.27. The business's 50 day moving average price is $0.40 and its 200-day moving average price is $0.56. Vaxart has a 52-week low of $0.29 and a 52-week high of $1.07.

Hedge Funds Weigh In On Vaxart

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its position in shares of Vaxart by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company's stock worth $1,723,000 after buying an additional 57,911 shares in the last quarter. Silverarc Capital Management LLC lifted its position in shares of Vaxart by 7.8% in the fourth quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock worth $714,000 after buying an additional 77,782 shares in the last quarter. Squarepoint Ops LLC lifted its position in shares of Vaxart by 95.0% in the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock worth $342,000 after buying an additional 251,789 shares in the last quarter. Jones Financial Companies Lllp lifted its position in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company's stock worth $196,000 after buying an additional 478,111 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Vaxart in the fourth quarter worth about $129,000. 18.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Steven Lo bought 100,000 shares of the business's stock in a transaction that occurred on Monday, May 19th. The stock was bought at an average cost of $0.49 per share, with a total value of $49,000.00. Following the completion of the purchase, the insider now owns 100,000 shares of the company's stock, valued at approximately $49,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.90% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.